Focus issue
Drug-eluting stents: TAXUS-IV: Editorial Comment
Surrogates, substudies, and real clinical end points in trials of drug-eluting stents*

https://doi.org/10.1016/j.jacc.2005.01.005Get rights and content
Under an Elsevier user license
open archive

Cited by (0)

*

Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.

1

Dr. Kereiakes has a consulting agreement with Advanced Stent Technologies, Conor MedSystems, Inc., Cordis Corporation, and Guidant Corporation.

2

Dr. Krucoff has grants/consulting contracts with Boston Scientific Corporation, Inc., Medtronic, Inc., Guidant Corporation, Cordis Corporation, and Johnson & Johnson.